Información del artículo
Atazanavir es un inhibidor de la proteasa indicado, en combinación con otros antirretrovirales, como tratamiento inicial de la infección por el virus de la inmunodeficiencia humana (VIH) o en pacientes pretratados. El tratamiento antirretroviral basado en atazanavir se ha relacionado con una baja frecuencia de hepatotoxicidad, tanto en ensayos clínicos como en estudio de cohortes. Sin embargo, el hallazgo de hiperbilirrubinemia ha resultado común en estos estudios, aunque usualmente no es una causa para la retirada del tratamiento. En pacientes coinfectados por virus de la hepatitis B (VHB) o C (VHC), el grado de respuesta virológica a atazanavir no se encuentra afectada y la incidencia de efectos adversos, salvo en la mayor incidencia de hepatotoxicidad, no es superior a la de los sujetos no coinfectados. La incidencia de hepatotoxicidad grave (grado 3-4) en pacientes coinfectados por el VIH y el VHC que reciben combinaciones de fármacos que incluyen atazanavir es de un 6%. Atazanavir tiene un favorable perfil de tolerabilidad y seguridad en pacientes coinfectados por virus de la hepatitis, incluso en presencia de fibrosis significativa. La menor relación de atazanavir con el desarrollo de resistencia a la insulina, hecho que se ha relacionado con una mayor velocidad de progresión de la fibrosis hepática y una menor tasa de respuesta al tratamiento, supondría un beneficio añadido del uso de atazanavir en pacientes coinfectados y podría servir de argumento adicional para su empleo en estos pacientes.
Palabras clave:
Atazanavir
VIH-1
Virus hepatitis C
Virus hepatitis B
Atazanavir is a protease inhibitor indicated, in combination with other antiretrovirals, as an initial treatment of HIV infection or in previously treated patients. Antiretroviral treatment based on atazanavir has been associated with a low incidence of hepatotoxicity, both in Clinical Trials as well as in cohort studies. However, the finding of hyperbilirubinaemia has been common in these studies, although it usually does not involve withdrawing the treatment. In patients co-infected with hepatitis B or C, the level of virological response to does not appear to be affected and the incidence of adverse effects, except the higher incidence of hepatotoxicity, is no higher than in non-coinfected subjects. The incidence of severe hepatotoxicity (grade 3-4) in patients coinfected by HIV and HVC who receive drug combinations that contain atazanavir is 6%. Atazanavir has a favourable tolerance and safety profile in patients coinfected with hepatitis virus even in the presence of significant fibrosis. The lower association of atazanavir with the development of insulin resistance, a fact that has been associated with increasing the progression to hepatic fibrosis and lower treatment response rates, could be an added benefit of the use atazanavir in coinfected patients and could serve as an additional argument for its use in these patients.
Key words:
Atazanavir
HIV-1
Hepatitis virus C
Hepatitis virus B
El Texto completo está disponible en PDF
Bibliografía
[1.]
V.D. Lima, R.S. Hogg, P.R. Harrigan, et al.
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
AIDS, 21 (2007), pp. 685-692
[2.]
Department of Human Health Service Panel on Antiretroviral Guidelines for Adults and Adolescents. Guideline for the use of antiretroviral agents in HIV-1-infected adults and adolescents [accedido 29 Ene 2008]. Disponible en: http://AIDSinfo.nih.gov
[3.]
Panel de expertos de GESIDA y Plan Nacional sobre el Sida. Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana (actualización enero de 2008). Disponible en: www.gesida.seimc.org
[4.]
K. Squires, A. Lazzarin, J.M. Gatell, W.G. Powderly, V. Pokrovskiy, F. Delfraissy, et al.
Comparison of once-daily atazanavir to efavirenz each in combination with fixed-dose zidovudina and lamivudine, as initial therapy for patients infected with HIV.
J Acquir Immune Defic Syndr, 36 (2004), pp. 1011-1019
[5.]
M. Johnson, B. Grinsztejn, C. Rodríguez, et al.
96-week comparison of oncedaily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
AIDS, 20 (2006), pp. 711-718
[6.]
J.M. Molina, J. Andrade-Villanueva, J. Echevarria, et al.
Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine in ARV-naive HIV-1- infected subjects: The Castle study, 48-week results.
Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, 3-6 February,
[7.]
J.M. Gatell, T. Branco, L. Sasset, et al.
Efficacy and safety of atazanavir (ATV) based HAART in virologically suppressed subjects switched from lopinavir/ ritonavir (LPV/RTV) treatment.
Program and abstracts of the XVI International AIDS Conference; August 13-18,
[8.]
D. Konopnicki, A. Mocroft, S. de Wit, et al.
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS, 19 (2005), pp. 593-601
[9.]
L.I. Backus, B.R. Phillips, D.B. Boothroyd, et al.
Effects of hepatitis C virus coinfection on survival in veterans with HIV treated with highly active antiretroviral therapy.
J Acquir Immune Defic Syndr, 39 (2005), pp. 613-619
[10.]
J. Macías, I. Melguizo, F.J. Fernández-Rivera, et al.
Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients on potent antiretroviral therapy.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 775-781
[11.]
A. Mocroft, B. Ledergerber, C. Katlama, et al.
Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Lancet, 362 (2003), pp. 22-29
[12.]
A. Mocroft, R. Brettle, O. Kirk, et al.
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study.
AIDS, 16 (2002), pp. 1663-1671
[13.]
D. Salmon-Ceron, C. Lewden, P. Morlat, et al.
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.
J Hepatol, 42 (2005), pp. 799-805
[14.]
C. Lewden, D. Salmon, P. Morlat, et al.
Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.
Int J Epidemiol, 34 (2005), pp. 121-130
[15.]
Rosenthal E1Department of Internal Medicine, Hôpital de l’Archet 1, Nice, Pialoux G, Bernard N, et al. Liver-related mortality in human-immunodeficiency- virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat. 2007;14:183-8.
[16.]
The Data Collection on Adverse Events of Anti-HIV Drugs Study group.
Liver-related deaths in persons infected with the human immunodeficiency virus, The D:A:D Study.
Arch Intern Med, 166 (2006), pp. 1632-1641
[17.]
E. Martinez, A. Milinkovic, E. Buira, et al.
Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
HIV Med, 8 (2007), pp. 251-258
[18.]
Y. Benhamou, M. Bochet, V. Di Martino, et al.
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients.
Hepatology, 30 (1999), pp. 1054-1058
[19.]
C.S. Graham, L.R. Baden, E. Yu, J.M. Mrus, T. Heeren, M.J. Koziel.
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analisis.
Clin Infect Dis, 33 (2001), pp. 562-569
[20.]
J.A. Pineda, M. Romero-Gómez, F. Díaz-García, et al.
HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.
Hepatology, 41 (2005), pp. 779-789
[21.]
N. Merchante, J.A. Giron-Gonzalez, M. Gonzalez-Serrano, et al.
Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease.
AIDS, 20 (2006), pp. 49-57
[22.]
M. Puoti, R. Bruno, V. Soriano, et al.
Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome.
AIDS, 18 (2004), pp. 2285-2293
[23.]
N. Bräu, R.K. Fox, P. Xiao, K. Marks, et al.
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a US-Canadian multicenter study.
J Hepatol, 47 (2007), pp. 447-450
[24.]
M.M. De Maat, A.D. Huitema, J.W. Mulder, P.L. Meenhorst, E.C. Van Gorp, J.H. Beijnen.
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
Br J Clin Pharmacol, 54 (2002), pp. 378-385
[25.]
M.S. Sulkowski.
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Clin Infect Dis, 38 (2004), pp. S90-S97
[26.]
M. Regazzi, R. Maserati, P. Villani, et al.
Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected patients.
Antimicrob Agents Chemother, 49 (2005), pp. 643-649
[27.]
M. Bonacini.
Liver injury during highly active antiretroviral therapy: The effects of hepatitis C coinfection.
Clin Infect Dis, 38 (2004), pp. S104-S108
[28.]
A. Rivero, J.A. Mira, J.A. Pineda.
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.
J Antimicrob Chemother, 59 (2007), pp. 342-346
[29.]
M.S. Sulkowski, D.L. Thomas, R.E. Chaisson, R.D. Moore.
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.
JAMA, 283 (2000), pp. 74-80
[30.]
M.S. Sulkowski, S.H. Mehta, R.E. Chaisson, D.L. Thomas, R.D. Moore.
Hepatotoxicity associated with protease inhibitor-based regimens with or without concurrent ritonavir.
AIDS, 18 (2004), pp. 2277-2284
[31.]
A. Aceti, C. Pasquazzi, B. Zechini, C. De Bac.
Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.
J Acquir Immune Defic Syndr, 29 (2002), pp. 41-48
[32.]
M.S. Sulkowski, D.L. Thomas, S.H. Mehta, R.E. Chaisson, R.D. Moore.
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Hepatology, 35 (2002), pp. 182-188
[33.]
U. Spengler, M. Lichterfeld, J.K. Rockstroth.
Antiretroviral therapy- a challenge for the hepatologist?.
J Hepatol, 36 (2002), pp. 283-294
[34.]
L. Aranzabal, J.L. Casado, J. Moya, et al.
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Clin Infect Dis, 40 (2005), pp. 588-593
[35.]
J.A. Mira, J. Macías, J.A. Girón-González, et al.
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
J Antimicrob Chemother, 58 (2006), pp. 140-146
[36.]
P. Labarga, V. Soriano, M.E. Vispo, et al.
Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
J Infect Dis, 196 (2007), pp. 670-676
[37.]
F. Carrat, F. Bani-Sadr, S. Pol, et al.
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
JAMA, 292 (2004), pp. 2839-2848
[38.]
M. Laguno, J. Murillas, J.L. Blanco, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.
AIDS, 18 (2004), pp. F27-36
[39.]
A. Cargnel, E. Angeli, A. Mainini, et al.
Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Antivir Ther, 10 (2005), pp. 309-317
[40.]
M.P. Manns, J.G. McHutchison, S.C. Gordon, et al.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.
Lancet, 358 (2001), pp. 958-965
[41.]
S.J. Hadziyannis, J.r. Sette H, T.R. Morgan, et al.
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Ann Intern Med, 140 (2004), pp. 346-355
[42.]
J.A. Pineda, J.A. García-García, M. Aguilar-Guisado, M.J. Ríos-Villegas, J. Ruiz- Morales, A. Rivero, et al.
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Hepatology, 46 (2007), pp. 622-630
[43.]
M.S. Sulkowski.
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Clin Infect Dis, 38 (2004), pp. S90-S97
[44.]
R.L. Murphy, I. Sanne, P. Cahn, et al.
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results.
AIDS, 17 (2003), pp. 2603-2614
[45.]
R. Wood, P. Phanuphak, P. Cahn, et al.
Long-term efficacy and 397 safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
J Acquir Immune Defic Syndr, 36 (2004), pp. 684-692
[46.]
J.A. Pineda, R. Palacios, A. Rivero, et al.
Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir.
J Antimicrob Chemoter, 57 (2006), pp. 1016-1017
[47.]
J.A. Pineda, J. Santos, A. Rivero, L. Abdel-Kader, R. Palacios, A. Camacho, et al.
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
J Antimicrob Chemother, 61 (2008), pp. 925-932
[48.]
J. Casado, L. Aranzabal, J. Moya, et al.
Risk of liver toxicity inHCV/HIV coinfected patients with advanced chronic liver disease or cirrhosis receiving nevirapine, efavirenz or lopinavir/r.
Abstracts of the Third International AIDS Society Conference on HIV Pathogenesis and Treatment,
[49.]
Y. Benhamou, V. Mats, D. Walczak.
Systemic overview of HAART-associated liver enzyme elevations in patients infected with HIV and co-infected with HCV.
Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA,
[50.]
L. Fartoux, A. Poujol-Robert, J. Guechot, D. Wendum, R. Poupon, L. Serfaty.
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C.
Gut, 54 (2005), pp. 1003-1008
[51.]
R. D'Souza, C.A., GR Foster Sabin.
Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy.
Am J Gastroenterol, 100 (2005), pp. 1509-1515
[52.]
M.A. Noor, O.P. Flint, J.F. Maa, R.A. Parker.
Efects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.
AIDS, 10 (2006), pp. 1813-1821
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
